PEPTIDEPEDIA.US
All peptides
Mitochondrial & Metabolic HealthGrade A

MOTS-c

Also known as Mitochondrial Open Reading Frame of the 12S rRNA-c

A mitochondrial-derived peptide involved in cellular metabolic signaling and adaptive responses to metabolic stress.

Regulatory status
Investigational / research peptide

MOTS-c is not an approved weight-loss, diabetes, anti-aging, or performance therapy in any jurisdiction.

Half-life
Human pharmacokinetic half-life not established.

Circulating endogenous MOTS-c has been measured in humans, but administration pharmacokinetics in humans are not reliably characterized.

Route
Subcutaneous and intraperitoneal in published experimental studies

Research use / investigational. No validated clinical route in humans.

Evidence
Multiple randomized controlled trials in humans

Mechanism of action

MOTS-c is encoded within the mitochondrial 12S rRNA and participates in mitochondrial-to-nuclear communication. Research describes involvement in AMPK-related signaling, cellular stress responses, folate-methionine cycle intermediates, glucose metabolism, and energy homeostasis. Most mechanistic characterization comes from cell and animal models rather than human administration studies, and framing MOTS-c simply as an 'exercise mimetic' oversimplifies this biology.

Mitochondrial signalCellular stress responseAMPK-related signalingGlucose & energy homeostasis

Studied and reported uses

  • Metabolic health

    Investigated for potential roles in insulin sensitivity and metabolic regulation. Preclinical studies suggest metabolic effects; human administration data are limited.

  • Glucose utilization

    Preclinical studies suggest effects on cellular glucose handling and substrate use.

  • Exercise physiology

    Endogenous MOTS-c levels have been studied in humans in relation to physical activity and metabolic stress (observational measurement, not administration).

  • Mitochondrial signaling

    Investigated as part of mitochondrial-to-nuclear communication and retrograde signaling.

  • Healthy aging research

    Mitochondrial-derived peptides are an active area of aging-biology research, including associations with age and metabolic status.

Dosing information

Clinical research informationNo established human dosing regimen exists for synthetic MOTS-c.
Study protocolsReported administration protocols come primarily from animal studies (dose used in that study, not a recommended dose).

Ranges are reported from literature and clinical labeling for reference only. They are not a dosing recommendation.

Published research has used different experimental protocols depending on the compound, formulation, route, indication and study design. These study protocols should not be interpreted as established clinical dosing recommendations.

Important pharmacology

Endogenous measurement vs administration

Human research measuring circulating endogenous MOTS-c is a separate evidence stream from human therapeutic administration of synthetic MOTS-c. Associations with fitness, age, or metabolic status do not demonstrate that injecting MOTS-c produces those outcomes.

AMPK-related signaling

AMPK involvement is described largely in cell and rodent models; the magnitude and relevance of this pathway in humans after exogenous administration is not established.

Side effects

  • Human adverse-event data limited
  • Injection-site discomfort reported anecdotally
  • Possible glycemic changes (theoretical)

There is no adequately characterized human safety profile for administered synthetic MOTS-c. Long-term tolerability is unknown.

Research evidence

Discovery of MOTS-c as a mitochondrial-derived peptide

In Vitro / Animal: identification of MOTS-c and description of metabolic effects in cells and mice.

Insulin sensitivity in rodent models

Animal: preclinical studies suggest improved insulin sensitivity and protection against diet-induced metabolic dysfunction.

Human endogenous MOTS-c and exercise

Human Observational: circulating MOTS-c has been measured before and after exercise and across age groups.

Human administration evidence

Controlled human trials of exogenous MOTS-c administration are lacking; efficacy in humans is not established.

Scientific references

  • The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance

    Lee C, et al. · Cell Metabolism · 2015

    Cell Metabolism (PubMed-indexed)

    AnimalPubMedDOI

  • Exercise induces the release of MOTS-c in humans

    Physiological Reports / JCEM · 2018

    Human observational exercise physiology studies

    Human ObservationalPubMed

  • Mitochondrial-derived peptides in aging and metabolic disease

    PubMed-indexed review of mitochondrial microproteins

    ReviewPubMed

  • MOTS-c regulates AMPK and folate cycle metabolism

    Mechanistic cell-based studies (PubMed-indexed)

    In VitroPubMed

  • MOTS-c and nuclear gene expression regulation

    Cell Metabolism · 2018

    PubMed-indexed mechanistic research

    MechanisticPubMed